328 related articles for article (PubMed ID: 17001676)
1. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
Biswas DK; Iglehart JD
J Cell Physiol; 2006 Dec; 209(3):645-52. PubMed ID: 17001676
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
3. [The nuclear factor kappa B activation: the key step of cell proliferation in estrogen receptor-negative breast cancer cells].
Wang HJ; Wu ZY; Fan P; Bian JM
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):1014-6. PubMed ID: 16194364
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
Gionet N; Jansson D; Mader S; Pratt MA
J Cell Biochem; 2009 Jun; 107(3):448-59. PubMed ID: 19350539
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
[TBL] [Abstract][Full Text] [Related]
7. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
9. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
10. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
Zhou Y; Eppenberger-Castori S; Marx C; Yau C; Scott GK; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2005 May; 37(5):1130-44. PubMed ID: 15743683
[TBL] [Abstract][Full Text] [Related]
11. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
12. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines.
Yamaguchi N; Ito T; Azuma S; Ito E; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Watanabe S; Semba K; Inoue J
Cancer Sci; 2009 Sep; 100(9):1668-74. PubMed ID: 19538528
[TBL] [Abstract][Full Text] [Related]
15. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population.
Pratt MA; Tibbo E; Robertson SJ; Jansson D; Hurst K; Perez-Iratxeta C; Lau R; Niu MY
Oncogene; 2009 Jul; 28(30):2710-22. PubMed ID: 19483731
[TBL] [Abstract][Full Text] [Related]
16. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
17. Crossroads of estrogen receptor and NF-kappaB signaling.
Biswas DK; Singh S; Shi Q; Pardee AB; Iglehart JD
Sci STKE; 2005 Jun; 2005(288):pe27. PubMed ID: 15956359
[TBL] [Abstract][Full Text] [Related]
18. Targeting the NF-kappa B pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs.
Monks NR; Pardee AB
J Cell Biochem; 2006 May; 98(1):221-33. PubMed ID: 16408291
[TBL] [Abstract][Full Text] [Related]
19. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry: a new approach for the molecular profiling of breast cancer.
Lostumbo A; Mehta D; Setty S; Nunez R
Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
